Last reviewed · How we verify

NCT05145517: FLOWGRAFT

A Post-Market Clinical Follow-up Study in Patients Treated With Vascular Grafts

Recruiting now Last updated 19 May 2022
What this trial tests

trial testing Open repair in Vascular Diseases in 500 participants. Currently enrolling.

Timeline
6 December 2021
Primary endpoint
1 October 2024
30 March 2030

Quick facts

Lead sponsorJOTEC GmbH
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date6 December 2021
Primary completion1 October 2024
Estimated completion30 March 2030
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

JOTEC GmbH

Who can join

18 and older, any sex, with Vascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The FLOWGRAFT post-market clinical follow-up study is undertaken to show the safety and performance of FlowWeave Bioseal, FlowNit Bioseal, FlowLine Bipore and FlowLine Bipore Heparin (combined named as Vascular Grafts) in the treatment of arterial diseases, such as dissection, aneurysm, intramural hematoma (IMH), penetrating aortic ulcer (PAU), contained rupture, stenosis in the aorta or peripheral arteries (lower limbs). This includes the use of FlowWeave Bioseal or FlowNit Bioseal for debranching of the head vessels in an alone standing procedure. Furthermore, it includes the use of the FlowLine Bipore and FlowLine Bipore Heparin Grafts as arterious-venous (AV) shunt.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Open repair

Trials testing the same drug.

Other recruiting trials for Vascular Diseases

Currently open trials in the same condition.

Other JOTEC GmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05145517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing